Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Feb 21;8(8):13312-13319.
doi: 10.18632/oncotarget.14516.

Poly(C)-binding protein 1 mediates drug resistance in colorectal cancer

Affiliations

Poly(C)-binding protein 1 mediates drug resistance in colorectal cancer

Jiani Guo et al. Oncotarget. .

Abstract

Oxaliplatin (L-OHP) is standard treatment for colorectal cancer. However, resistance to L-OHP often leads to treatment failure or cancer relapse. Understanding of the mechanism underlying L-OHP resistance is important to overcome the resistance and improve colorectal cancer treatment. This study aimed to identify new proteins that mediates L-OHP resistance in colorectal cancer and elucidate their mode of function. HT-29 cells were exposed to gradually increased concentration of L-OHP to select L-OHP resistant HT-29/L-OHP cell line. Proteomic analysis of HT-29 and HT-29/L-OHP cells were performed to identify differentially expressed proteins, including Poly(C)-binding protein 1 (PCBP1). PCBP1 expression level in 20 cases of L-OHP sensitive patients and 20 cases of L-OHP refractory patients was analyzed by immunohistochemistry. Chemoresistance and Akt activation in HT-29 and HT-29/L-OHP cells were analyzed by MTT assay and Western blot analysis. We identified 37 proteins showing differential expression in HT-29/L-OHP and HT-29 cells. In particular, PCBP1 protein level increased 15.6 fold in HT-29/L-OHP cells compared to HT-29 cells. Knockdown of PCBP1 sensitized HT-29/L-OHP and HT-29 cells to L-OHP, while overexpression of PCBP1 increased L-OHP resistance in HT-29 cells. In addition, PCBP1 expression was significantly higher in tumor samples from L-OHP refractory patients than in those from L-OHP responsive patients. Furthermore, we found that knockdown of PCBP1 inhibited the activation of Akt in HT-29/L-OHP and HT-29 cells. In conclusion, our findings suggest that PCBP1 is a molecular marker of L-OHP resistance in colorectal cancer and a promising target for colorectal cancer therapy.

Keywords: chemoresistance; colorectal cancer; oxaliplatin; poly(C)-binding protein 1.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST

The authors declare that there are no conflicts of interest.

Figures

Figure 1
Figure 1. Establishment of L-OHP resistant HT-29 cell line
(A) IC50 of HT-29 parental cells and HT-29/L-OHP cells. (B) Western blot analysis of MRP and P-gp expression in HT-29 parental cells and HT-29/L-OHP cells. β-actin was loading control.
Figure 2
Figure 2. Proteomic analysis of proteins involved in L-OHP resistance in HT-29/L-OHP cells
(A) 2D gel electrophoresis of HT-29 parental cells and HT-29/L-OHP cells. Arrows indicated protein spots with more than two fold expression difference between HT-29 parental cells and HT-29/L-OHP cells. (B) Enlarged view of protein spots of PCBP1, TUBB2A, ANXA3 and STIP1. (C) MALDI-TOF/TOF analysis of 37 identified proteins. (D) Western blot analysis of PCBP1, ANXA3, and STIP1 expression in HT-29/L-OHP cells. β-actin was loading control.
Figure 3
Figure 3. PCBP1 increased L-OHP resistance in HT-29 cells
(A) Western blot analysis of PCBP1 levels in HT-29, HT-29+PCBP1, HT-29-PCBP1, HT-29/L-OHP and HT-29/L-OHP-PCBP1 cells. β-actin was loading control. *P < 0.05, **P < 0.01 vs. corresponding control. (B) Cell survival curve of HT-29/L-OHP cells with or without PCBP1 knockdown, and cell survival curve of HT-29 cells with or without PCBP1 knockdown and with exogenous PCBP1 expression. (C) IC50 of HT-29/L-OHP cells with or without PCBP1 knockdown, and IC50 of HT-29 cells with or without PCBP1 knockdown and with exogenous PCBP1 expression. *P < 0.05 vs. corresponding control.
Figure 4
Figure 4. Higher PCBP1 expression in samples from L-OHP resistant patients
(A) Representative strong staining of PCBP1 in tumor tissue from L-OHP resistant patient. (B) Representative weak staining of PCBP1 in peri-cancerous tissue from L-OHP resistant patient. (C) Representative weak staining of PCBP1 in tumor tissue from L-OHP sensitive patient. (D) Representative weak staining of PCBP1 in peri-cancerous tissue from L-OHP sensitive patient. Scale bar: 50 μm. (E) PCBP1 level was significantly higher in L-OHP resistant tumor tissue than that in L-OHP sensitive tumor tissue or peri-cancerous tissue (P < 0.05).
Figure 5
Figure 5. Knockdown of PCBP1 led to decreased Akt Ser473 phosphorylation in HT-29 and HT-29/L-OHP cells
Western blot analysis of PCBP1, p-Ser473 Akt and total Akt levels in HT-29 and HT-29/L-OHP cells transfected with scramble siRNA (C) or PCBP1 siRNA (shPCBP1). Β-actin was loading control.

Similar articles

Cited by

References

    1. Knudsen AB, Zauber AG, Rutter CM, Naber SK, Doria-Rose VP, Pabiniak C, Johanson C, Fischer SE, Lansdorp-Vogelaar I, Kuntz KM. Estimation of Benefits, Burden, and Harms of Colorectal Cancer Screening Strategies: Modeling Study for the US Preventive Services Task Force. JAMA. 2016;315:2595–2609. - PMC - PubMed
    1. Alcindor T, Beauger N. Oxaliplatin: a review in the era of molecularly targeted therapy. Cur Oncol. 2011;18:8. - PMC - PubMed
    1. Sato S, Itamochi H, Kigawa J, Oishi T, Shimada M, Sato S, Naniwa J, Uegaki K, Nonaka M, Terakawa N. Combination chemotherapy of oxaliplatin and 5-fluorouracil may be an effective regimen for mucinous adenocarcinoma of the ovary: A potential treatment strategy. Cancer Sci. 2009;100:546–551. - PMC - PubMed
    1. El-akawi Z, Abu-hadid M, Perez R, Glavy J, Zdanowicz J, Creaven PJ, Pendyala L. Altered glutathione metabolism in oxaliplatin resistant ovarian carcinoma cells. Cancer Lett. 1996;105:5–14. - PubMed
    1. Arnould S, Hennebelle I, Canal P, Bugat R, Guichard S. Cellular determinants of oxaliplatin sensitivity in colon cancer cell lines. Eur J Cancer. 2003;39:112–119. - PubMed

MeSH terms